A Phase 1, Open-label, Single Center Study of KYV-101, an Autologous Fully-human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis (S3.001)

To assess the feasibility and safety of treating non-relapsing progressive phenotypes of Multiple Sclerosis with chimeric antigen receptor (CAR-T) immunotherapy with a CD-19+ binding site.

Authors

Kristin Galetta (ORCID: https://orcid.org/0000-0002-3783-9788)
Robert Lowsky
Julia Sumera
Anna Tomczak (ORCID: https://orcid.org/0009-0000-2973-8592)
Jeffrey Dunn (ORCID: https://orcid.org/0000-0002-1721-6081)
Emma Martínez
Garrett Timmons
Crystal Ton-Nu

Institutions

Stanford Blood Center (US)
Stanford University (US)

Publication Details

Journal: Neurology
Published: 2025-04-07
DOI: https://doi.org/10.1212/wnl.0000000000212317
Citations: 1
Primary Topic: CAR-T cell therapy research
Type: article
Field-Weighted Citation Impact: 1.05

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

A Phase 1, Open-label, Single Center Study of KYV-101, an Autologous Fully-human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis (S3.001)

Kristin Galetta, Robert Lowsky, Julia Sumera, Anna Tomczak et al.

Apr 7, 2025

1 citations

Neurology

CAR-T cell therapy research

1.05

article

A Phase 1, Open-label, Single Center Study of KYV-101, an Autologous Fully-human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis (S3.001)

Kristin Galetta, Robert Lowsky, Julia Sumera, Anna Tomczak, Jeffrey Dunn, Emma Martínez, Garrett Timmons, Crystal Ton-Nu

April 7, 2025article en

1 citations

Abstract

To assess the feasibility and safety of treating non-relapsing progressive phenotypes of Multiple Sclerosis with chimeric antigen receptor (CAR-T) immunotherapy with a CD-19+ binding site.

NeurologyVol. 104(7_Supplement_1)

Stanford Blood Center (US), Stanford University (US)

Good health and well-being

Openalex Percentile: Top 23%

CAR-T cell therapy research

1.05

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.